Search results
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 4 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks via Yahoo Finance· 10 hours agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's...
Vanguard Group Inc. Acquires 6,572 Shares of Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 4 days agoVanguard Group Inc. boosted its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission ...
Safeguard Financial LLC Takes $235,000 Position in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 8 hours agoSafeguard Financial LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm ...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 3 days agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
Cardinal Capital Management Inc. Sells 3,561 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 8 hours agoCardinal Capital Management Inc. cut its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 1.8% during the 1st quarter, according to the company in its most recent Form 13F filing ...
AbbVie Inc. (NYSE:ABBV) Shares Sold by Stableford Capital II LLC
ETF DAILY NEWS· 8 hours agoStableford Capital II LLC decreased its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 6.2% in the 1st quarter, Holdings Channel reports. The firm owned 5,038 shares of the company’s stock ...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
Morningstar· 1 day agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 2 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 1 day agoThis approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S., including psoriatic arthritis, plaque psoriasis& ...